Skip to main content

Varun Sharma · Founder, CEO & CTO

Building the systems medicine still needs

Varun Sharma is a Glasgow born British Indian pharmaceutical entrepreneur, the founder of NEUVIOR and the product architect behind PHARMORIS. His work connects medicines, technology and the operating discipline required to turn insight into action.

Varun Sharma, Founder, CEO and CTO of NEUVIOR
Glasgow born | British Indian perspectiveNEUVIOR | Founder, CEO & CTOPHARMORIS | Product architect

Origins

The operating education began behind a Glasgow shop counter.

In his published first person writing, Varun traces his earliest business education to his father’s corner shop. Stock had to move, cash had to be protected, customers had to trust you and a poor decision became visible quickly. The lesson was not glamour; it was responsibility.

That instinct stayed with him as his attention moved towards medicines, technology and complex institutions. He became interested in the point where good information stops being enough, where a decision needs an owner, a route through implementation and a result people can review.

Varun Sharma walking in London at night
01

Trust is operational

Customers remember whether the promise, product and action matched, not how sophisticated the explanation sounded.

Corner shop lesson
02

Cash and time expose truth

A useful system must respect the resources, constraints and people carrying the work every day.

Operating lesson
03

The detail compounds

Small decisions become a reputation, an operating model and eventually the institution you are building.

Founder lesson

Why he built NEUVIOR

You already have medicines evidence. The gap is what happens next.

Varun’s founder thesis is that modern medicines systems do not mainly suffer from a lack of analysis. They suffer when evidence, authority, delivery and review become disconnected across teams, inboxes and institutional boundaries.

He founded NEUVIOR to build the company around that gap. PHARMORIS is the first focused product: a human governed operating layer intended to help an authorised team move from a medicines signal to an ActionCase, a decision, coordinated work and a reviewable result.

01

Company direction

Set NEUVIOR’s commercial direction and connect the immediate product to a wider pharmaceutical thesis.

Founder and CEO
02

Product architecture

Lead the model connecting sources, CandidateSignals, human triage, ActionCases, delivery and ValueReview.

CTO and product architect
03

Public argument

Make the case for implementation discipline in medicines, pharmaceutical trade and complex technology systems.

Founder commentary

Founder led momentum

Use the opening wins to earn the next level of company.

NEUVIOR has been selected for non-dilutive support for defined project work. Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome. Varun has also developed a growing public voice across pharmaceutical, technology and business publications.

For Varun, the purpose of early support and attention is not to look larger than the business. It is to build the product, evidence, relationships and operating capability required for NEUVIOR to become the pharmaceutical institution it is designed to be.

01

Source linked support

Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.

Company public record
02

PHARMORIS

The first product through which the company can prove that medicines evidence becomes more useful when action remains governed and owned.

Product architecture
03

Published thinking

Commentary on neurodivergent founders, medicines implementation, pharmaceutical trade and the systems behind execution.

BusinessCloud to Pharmaceutical Technology

Evidence index | Reviewed 20 August 2026

Read the record by evidence class, not by logo count.

This founder biography separates publisher-originated coverage, material written by or attributed to Varun, NEUVIOR-owned material and future ambition. Publication proves that a record exists. It does not by itself prove adoption, technical validation, regulatory authority, customer outcomes or endorsement.

No current newsroom entry is classified as fully independent reporting. Publisher records derived from announcements, roundups, syndication or partner material retain those labels. The distinction is deliberate and will change only when the source relationship changes.

01Independent coverage
None currently verified as fully independent reporting. Publisher-hosted company records remain indexed by their actual source relationship rather than promoted as third-party validation.Current evidence state | None
02Authored commentary
Bylined or attributed commentary includes medicines implementation, pharmaceutical quality, founder operating discipline and UK-India pharmaceutical trade. These records establish publication and authorship, not professional or regulatory credentials.External publisher | Founder voice
03Company material
NEUVIOR Insights, governance proposals, product explanations and this biography are company-published material. They explain the operating thesis and evidence boundaries; they are not independent media coverage.Owned source | NEUVIOR
04Future ambition
Longer-term pharmaceutical development, laboratories, manufacturing and international institution-building remain direction to be earned through evidence, rights, capital, capability and approvals. They are not present operating claims.Forward thesis | Not current capability

Classified public record

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01Who is Varun Sharma?

Varun Sharma is the Founder, CEO and CTO of NEUVIOR. He leads company strategy, product architecture for PHARMORIS and NEUVIOR’s wider pharmaceutical direction.

02What shaped Varun Sharma’s approach to business?

In his published personal writing, Varun traces his operating instincts to his family’s Glasgow corner shop. Trust, stock, cash flow and daily decisions had immediate consequences there. That experience informs his focus on systems that turn complexity into owned action.

03What is Varun Sharma’s role in PHARMORIS?

Varun leads PHARMORIS product architecture and the operating thesis behind its evidence and action workflow. PHARMORIS remains governed by people and under controlled development.

04Where can I read Varun Sharma’s articles?

NEUVIOR’s Newsroom and Insights pages index Varun’s founder commentary and analysis, including work published by BusinessCloud, Startups Magazine, Manufacturing Chemist, PharmaTimes and Pharmaceutical Technology.